 Hepatotoxicity rifampin isoniazid drug-induced hepatitis Serologic markers hepatitis viruses children acute hepatitis antituberculosis therapy rifampin isoniazid aim contributory role viruses hepatic injury patients IgM antibodies Epidemiologic evidence possibility non-A non-B hepatitis children Hepatitis children severe tubercular disease study highlights endemicity viral hepatitis countries factors responsible incidence hepatotoxicity countries risk hepatotoxicity severe tubercular disease